Opipramol

In response to the clinical medication demand for mental disorders such as depression, tricyclic antidepressants, with their clear mechanism of action and stable therapeutic effect, are still a commonly used basic medication option in clinical practice. Opipramol, as one of the representative varieties of tricyclic antidepressants, can inhibit the reuptake of 5-hydroxytryptamine and norepinephrine by the central nervous system, and also has a certain sedative effect. It is not only applicable to patients with various types of depression, but also has a definite improvement effect on the depressed population with concomitant anxiety symptoms, and can also be used to relieve emotional disorders related to neurosis.

At present, the overall global market size of tricyclic antidepressants maintains steady growth. Among them, opipramol, with its long clinical application history and sufficient safety evidence, has stable demand in the field of maintenance treatment for mild to moderate depression. In terms of the domestic market, this variety has not been included in the scope of national centralized volume-based procurement for now. The existing supply is mainly generic drugs, and there is no publicly verifiable statistical data on the segmented market size.

The original research enterprise of opipramol is Bayer Vital GmbH, and the original research brand name is "Doxans". The protection period of its core compound patent has expired. The main dosage form of the original research product is tablet, and common specifications include 50mg, etc. The original research preparation of this variety has not been included in the China Listed Drug Catalogue, and there is no opipramol preparation variety that has been approved for marketing in China. As of the retrieval time, there is also no approved opipramol API registration number (DMF) on the CDE API registration platform. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of opipramol impurity reference standards. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. They fully meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the demand for impurity reference standards in the process of API R&D, quality research and production.